Core Viewpoint - The public fund market in China has kicked off the new year with the launch of 44 new funds, primarily focusing on equity products, indicating strong confidence in future market trends [2][4]. Fund Issuance Overview - A total of 44 new public funds were launched during the week of January 5 to January 9, 2026, with equity products being the main focus [4][8]. - Among the new funds, 19 were actively managed equity funds and 12 were index funds, with 16 of the actively managed funds being mixed equity funds [4][10]. Thematic Focus of New Funds - Many new funds are designed to fill gaps in existing product lines or to align with future market trends, such as themes related to dividends, overseas investments, technology, and consumption [2][5]. - Specific funds like Huatai-PineBridge Technology Leading focus on global competitiveness in Chinese technology, targeting areas such as AI innovation and semiconductor equipment [4][5]. Management and Strategy Insights - Experienced fund managers are at the helm of several new funds, such as Yang Dong's Guangfa Research Selection, which combines subjective research with quantitative models [5][10]. - The investment strategies of new funds include a focus on high-quality cyclical assets and sectors like internet, consumption, telecommunications, and traditional manufacturing [4][5]. Market Trends and Future Outlook - The public fund issuance in 2025 was significant, with 1,549 funds launched and a total fundraising of 1,204.139 billion yuan, marking the second-highest issuance year in history [9][10]. - The outlook for 2026 suggests a continuation of the trend with a balanced focus on equity and fixed income products, driven by the recovery of bond allocation value and the entry of long-term funds [10].

Group 1 - The structure of private investment continues to optimize, showing a trend towards practical and innovative sectors, with private investment in infrastructure steadily increasing by 3.5% year-on-year in the first eleven months of 2025 [1] - Private investment in the water management industry grew by 34.2%, while the aviation transport sector saw a 25.1% increase [1] - The scale of ultra-long-term special government bonds is expected to reach 1.3 trillion yuan in 2025, a significant increase of 800 billion yuan compared to 2024 [1] Group 2 - By the end of November 2025, the total social financing scale was 440.07 trillion yuan, with a year-on-year growth of 6.3% in loans to the real economy [2] - The banking sector reported a 21% year-on-year increase in loans to small and micro enterprises by the end of the third quarter [2] - A moderately loose monetary policy will continue to be implemented in 2026 to support effective investment [2] Group 3 - Private investment is a crucial support for stabilizing growth, adjusting structure, and promoting employment, with macro policies aimed at delivering benefits to business entities and stimulating private investment vitality [3] - The "one enterprise, one policy" approach enhances the investment confidence of private enterprises, as demonstrated by a small motorcycle export company that received a loan of 4.8 million yuan within five working days [3][4] - The financial support mechanism for small and micro enterprises has facilitated significant credit disbursement, with 768.19 billion yuan in loans provided by the end of November 2025 [4] Group 4 - Financial institutions are encouraged to enhance support for small and micro enterprises, aiming to expand private investment and boost development vitality [5] - The focus will be on improving financial support for key industrial chains and encouraging the development of financing products that meet private investment needs [5] - The collaboration between government, enterprises, and financial institutions is essential for achieving high-quality development in the bio-manufacturing industry [13] Group 5 - Companies like Yunnan Lishi Industrial Group have benefited from government policies that support private economic development, leading to significant investments in their core potato industry [6][7] - The company plans to deepen its supply chain and expand its market presence, supported by favorable policies and financial backing [8] - Changsha Jinlong Cable Technology Co., Ltd. has tripled its investment in 2025 and plans to further increase it in 2026, driven by confidence in market demand and supportive policies [9][11] Group 6 - Shanghai Kasei Biotechnology Co., Ltd. emphasizes the importance of stable R&D investment and long-term financial support for its growth [12] - The company has successfully raised approximately 5.5 billion yuan through its IPO, enabling significant expansion in investment and production scale [12] - The collaboration with financial institutions and government support is crucial for the company's future development and market expansion [12][13] Group 7 - Financial services in regions like Jinjiang are tailored to meet the unique needs of numerous small and micro enterprises, enhancing their operational stability and investment confidence [14][15] - The "factory quick loan" initiative allows companies to leverage their fixed assets for financing, facilitating smoother operations and growth [16] - The focus on providing long-term, stable financial support is essential for helping small enterprises concentrate on quality control and future investments [16]

措施在建设新型航空器总装制造能力方面，提出市区协同聚焦建设特色产业园区，加大产业用地、人才 服务、专项资金等要素资源支持力度，为落地的低空航空器总装制造及关键配套项目提供综合性保障。 对eVTOL、吨级工业级无人机等技术创新度高、产业化贡献突出的整机生产制造项目，给予最高不超 过1亿元支持。引导低空产业基金联动社会资本给予股权投资支持。 之所以将低空经济列为"十五五"产业新增长点，打造"世界eVTOL之都"，源于上海的产业基础。 低空经济是以 eVTOL、工业级无人机等新型航空器研制为核心竞争力，强化颠覆性技术创新引领，广 泛开展有人驾驶和无人驾驶航空器的低空飞行活动,驱动设计制造、运营、消费多领域融合发展的创新 性经济形态。上海作为中国最早发展低空经济的城市之一，在低空经济的重要载体——eVTOL方面拥 有着良好的产业基础。目前，上海拥有完善的低空经济生态圈，全国50%以上的 eVTOL 头部企业已选 择上海。御风航空、峰飞、时的、沃兰特、磐拓等eVTOL头部企业几乎全在上海，被称为"eVTOL五小 龙"。 另外金山区的"华东无人机基地"，成为全国首批"民用无人驾驶航空试验区"，是国内唯一一个以海岛为 应用 ...

之所以将低空经济列为"十五五"产业新增长点，打造"世界eVTOL之都"，源于上海的产业基础。 低空经济是以 eVTOL、工业级无人机等新型航空器研制为核心竞争力，强化颠覆性技术创新引领，广泛开展有人驾驶和无人驾驶航空器的低空飞行活动,驱 动设计制造、运营、消费多领域融合发展的创新性经济形态。上海作为中国最早发展低空经济的城市之一，在低空经济的重要载体——eVTOL方面拥有着 良好的产业基础。目前，上海拥有完善的低空经济生态圈，全国50%以上的 eVTOL 头部企业已选择上海。御风航空、峰飞、时的、沃兰特、磐拓等eVTOL 头部企业几乎全在上海，被称为"eVTOL五小龙"。 上海拟聚焦低空经济、商业航天、具身智能、生物制造、智能终端，使它们成为上海产业新增长点，力争"十五五"时期整体达到万亿元规模。 集聚全国50%以上eVTOL头部企业的上海，再发新政支持低空经济发展。 1月4日，《上海市关于链接长三角加快建设低空经济先进制造业集群的若干措施》（下称"措施"）公布，提出到2028年，上海低空经济核心产业规模达到 800亿元左右，形成低空新型航空器完整产业链体系，建设低空经济国家先进制造业集群，加快迈向比较优势凸 ...

Core Viewpoint - In the past year, China has achieved record highs in the number of approved innovative drugs and total external licensing transactions, with approximately 30% of global drug pipelines currently under research in China. The National Medical Products Administration (NMPA) will continue to promote resources towards innovative drugs with new mechanisms and targets, while institutional support for biopharmaceutical innovation is expected to improve the domestic payment system for innovative drugs [3][4][6]. Group 1: Innovative Drug Approvals - In 2025, China approved 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [3]. - Among the approved innovative drugs, domestic drugs accounted for over 85%, with 80.85% of chemical drugs and 91.30% of biological products being domestically developed [4][5]. - The quality of domestic drug development has improved, with China contributing nearly 50% to global early clinical pipelines for next-generation therapies like ADCs and bispecific/trispecific antibodies [5]. Group 2: Licensing Transactions - In 2025, the total amount of external licensing transactions for Chinese innovative drugs exceeded $130 billion, with over 150 transactions, doubling the previous year's total of $51.9 billion [6]. - The significant increase in licensing reflects international recognition of the value of Chinese innovative drugs, supported by ongoing reforms in drug review and approval processes [6][7]. Group 3: Policy and Market Environment - The NMPA plans to enhance support for urgently needed clinical drugs through expedited review channels and improve the protection of drug trial data and market exclusivity [7]. - The new foreign investment encouragement policy in the pharmaceutical sector signals China's openness to foreign capital in drug innovation, particularly in new target and mechanism development [8]. - Despite advancements, the market mechanisms for innovative drugs in China still require improvement, with current innovative drug market share at only 8.6% compared to 81.8% in the U.S., indicating a need for better payment and pricing structures [8][9]. Group 4: Market Growth Projections - A report predicts that the Chinese innovative drug market will reach approximately 550 billion RMB in 2024, growing to over 740 billion RMB in 2025, with a compound annual growth rate of 24.1% expected from 2024 to 2030 [10].

Core Insights - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historic high for the country [1][2] - The total value of innovative drug licensing transactions from China exceeded $130 billion in 2025, with over 150 transactions, also a record high [1][4] - Domestic innovative drugs accounted for over 85% of the newly approved drugs in 2025, indicating a strong growth in local pharmaceutical development [2][3] Group 1: Drug Approval and Market Dynamics - The National Medical Products Administration (NMPA) reported that 38 out of 47 chemical drugs approved in 2025 were domestically developed, representing 80.85% of the total [1] - Among the 23 biological products approved, 21 were domestic, accounting for 91.30% [1] - The number of innovative drugs in the pipeline in China represents approximately 30% of the global total, positioning China as the second-largest contributor worldwide [2] Group 2: International Recognition and Investment - The significant increase in licensing transactions reflects international recognition of the value of Chinese innovative drugs, with the total transaction amount doubling from the previous year [4] - The NMPA is committed to enhancing the approval process for urgently needed drugs, particularly those with new mechanisms and targets, to further stimulate innovation [5] - New policies encouraging foreign investment in the pharmaceutical sector signal China's openness to global capital in drug innovation [5] Group 3: Market Growth and Future Projections - The Chinese innovative drug market is projected to reach approximately 740 billion RMB in 2025, with an overall growth rate of about 35% [7] - By 2030, the market size is expected to exceed 2 trillion RMB, with a compound annual growth rate of 24.1% from 2024 to 2030 [7] - The introduction of the commercial insurance innovative drug directory is anticipated to enhance market access for high-priced innovative drugs, potentially increasing sales [6]

Core Insights - 2025 is marked as a pivotal year for the global economy, characterized by geopolitical conflicts, technological revolutions, policy shifts, and changes in consumer psychology [1][3] - The emergence of "new quality productivity" is highlighted as a key policy theme, transitioning from a conceptual framework to tangible industrial practices [3][5] Group 1: New Quality Productivity - "New quality productivity" was officially included in China's government work report for the first time, emphasizing its role in economic transformation [3][5] - AI models are evolving from general applications to industry-specific implementations, with significant investments in AI infrastructure increasing by 47% year-on-year [3][5] - Breakthroughs in renewable energy technologies, such as solar cell efficiency exceeding 26.5% and sodium-ion battery production costs dropping by 30%, are shifting the industry from subsidy-driven to technology-driven growth [3][5] Group 2: A-Share Market Dynamics - The A-share market experienced a remarkable recovery, with the Shanghai Composite Index rising from around 2800 points at the beginning of the year to approximately 3800 points by year-end, reflecting a growth of over 35% [5][6] - The market's upward trend is attributed to a combination of policy guidance, industrial upgrades, and valuation corrections, rather than broad-based speculation [5][6] - Key sectors such as AI computing, semiconductor equipment, and innovative pharmaceuticals saw gains exceeding 80%, while traditional sectors lagged [6] Group 3: U.S. Federal Reserve Policy - The Federal Reserve's policy oscillated between the end of the rate hike cycle and rising expectations for rate cuts, influencing global asset prices [7] - In December 2025, the Fed initiated a preventive rate cut of 25 basis points, signaling the onset of a more accommodative liquidity environment [7] Group 4: Consumer Market Trends - The consumer market in 2025 shifted from "revenge spending" to a more rational and segmented consumption pattern, with a focus on value [9] - New consumption trends emerged, including "cost-effective consumption" and "emotional value consumption," with significant growth in sectors like live events and cultural products [9][10] - The aging population's consumption potential is being realized, with a surge in demand for health monitoring devices and tailored travel experiences for seniors [9][10] Group 5: Marketing Innovations - The marketing landscape is undergoing a transformation, with a shift from budget competition to creative and technological integration due to the saturation of traffic growth [10] - AI is revolutionizing marketing processes, enhancing efficiency in content generation and customer engagement [10] Group 6: Future Economic Outlook - The economic landscape for 2026 is expected to be shaped by smoother interactions between technology, industry, and finance, with a focus on hard technology sectors [12][13] - The anticipated easing of monetary policy by the Federal Reserve and other central banks is expected to improve global liquidity conditions [12][13] - The rise of bio-manufacturing and the expansion of the carbon trading market are projected to create new market opportunities [12][13]

Group 1 - The core viewpoint of the article is that "微元合成" has recently secured nearly 300 million yuan in a new round of equity financing, with the funds aimed at accelerating the research and development of methanol-based biomanufacturing products [1][2] - The company has made significant progress in the development and commercialization of human and animal nutrition products, including allulose, lutein, and mannitol [1] - The financing will focus on the strategic area of "methanol biomanufacturing," with the company having already developed multiple high-efficiency methanol-assimilating strains [2][3] Group 2 - The company has received administrative approval from the National Health Commission for the production of allulose through a unique fermentation process, making it the first in China to do so [1][2] - The innovative "one-step fermentation method" simplifies the production process and significantly reduces costs compared to traditional methods [2] - The global production of chemical products is approximately 2.3 billion tons annually, while biobased products account for only 180 million tons, highlighting the need for non-food carbon sources in biomanufacturing [3] Group 3 - Methanol is identified as an ideal alternative carbon source, with China's coal-to-methanol capacity exceeding 10 million tons, representing 67% of the global total [3] - The company aims to utilize methanol to produce bulk amino acids, thereby reducing reliance on imported soybean meal and ensuring food security [3] - The development of non-food biobased products, particularly using agricultural residues and carbon dioxide, is gaining industry attention despite challenges in cost and logistics [3]

立足实体经济，意味着央企的发展方向、资源配置和创新活动，必须紧紧围绕工业制造等实体部门。我 国发展过程中，曾出现资本脱实向虚的错误苗头，带来巨大风险。国务院国资委近日发文，明确对服务 主业不力、脱实向虚等行为追究相应责任，给央企经营划定了红线。央企应落实相关要求，坚持有所为 有所不为，完善主责主业管理，进一步提高国有资本配置和运行效率。重视发展制造业，引领构建以先 进制造业为骨干的现代化产业体系。因企制宜培育新质生产力，更大力度布局新兴产业和未来产业，超 前谋划具身智能、生物制造等前沿赛道。着力打造市场化、专业化国有资本运作平台，当好发展实体经 济的长期资本、耐心资本和战略资本。 中国式现代化的物质技术基础是产业现代化。央企只有深耕实体经济，强化关键核心技术攻关，才能引 领现代化产业体系建设。必须强化科技创新主体地位，加强原始创新和关键核心技术攻关，提高基础研 究投入占比，特别是在研发周期长、投入大、其他企业涉足意愿不强或缺乏能力的领域坚定投入。紧盯 未来必争领域，勇当原创技术策源地和现代产业链"链长"，集中力量攻克一批辐射性、全局性、战略性 技术，产出一批原创性、引领性重大科技成果。着力打破创新成果转化运用 ...

深刻把握教育科技人才一体发展内在逻辑 为培育新质生产力提供坚实支撑 作者：王君松（山东科技大学党委书记） 习近平总书记强调，要统筹推进教育科技人才一体发展，筑牢新质生产力发展的基础性、战略性支撑。 党的二十届四中全会站在中国式现代化建设全局的战略高度，统筹教育强国、科技强国、人才强国建 设，明确提出"加快高水平科技自立自强，引领发展新质生产力"。高等教育作为教育筑基、科技突破、 人才培养的核心交汇点，肩负着打破要素壁垒、构建协同生态的重要使命，唯有以一体化思维破解发展 难题，以系统观念整合创新资源，才能为培育新质生产力提供坚实人才支撑，为中国式现代化注入强劲 动能。 深刻把握教育科技人才一体化与新质生产力发展的内在逻辑 教育、科技、人才是相互依存、相互促进的有机整体，三者共同构成推动高质量发展的核心支撑。三者 一体发展既是应对全球竞争、夯实发展根基的战略之举，也是顺应新质生产力内在发展规律的必然选 择。 华中科技大学机械科学与工程学院学生对机器 人进行代码调试。新华社发 从国际竞争趋势看，当前新一轮科技革命和产业变革加速推进，全球竞争的焦点已从传统要素比拼转向 创新能力较量。发达国家普遍通过构建"教育—科技— ...